You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 21, 2024

Bionpharma Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Bionpharma
International Patents:10
US Patents:5
Tradenames:65
Ingredients:60
NDAs:70
Patent Litigation for Bionpharma: See patent lawsuits for Bionpharma

Drugs and US Patents for Bionpharma

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bionpharma BENZONATATE benzonatate CAPSULE;ORAL 081297-002 Oct 30, 2007 AA RX No No ⤷  Subscribe ⤷  Subscribe
Bionpharma CLOBAZAM clobazam TABLET;ORAL 208825-002 Oct 22, 2018 AB RX No No ⤷  Subscribe ⤷  Subscribe
Bionpharma DROXIDOPA droxidopa CAPSULE;ORAL 213033-003 Apr 28, 2021 AB RX No No ⤷  Subscribe ⤷  Subscribe
Bionpharma VITAMIN D ergocalciferol CAPSULE;ORAL 080704-001 Approved Prior to Jan 1, 1982 AA RX No No ⤷  Subscribe ⤷  Subscribe
Bionpharma ZONISAMIDE zonisamide CAPSULE;ORAL 077813-002 Aug 16, 2006 AB RX No No ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Bionpharma Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0245997 C300002 Netherlands ⤷  Subscribe PRODUCT NAME: DOFETILIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/99/121/001 - EU/1/99/121/015 19991129
0994863 07C0037 France ⤷  Subscribe PRODUCT NAME: MODIFICATION CRISTALLINE A DU RUFINAMIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/06/378/001 DU 20070116; REGISTRATION NO/DATE AT EEC: EU/1/06/378/001-016 DU 20070116
0914118 SPC/GB07/002 United Kingdom ⤷  Subscribe SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB07/002 GRANTED TO NOVARTIS AG IN RESPECT OF THE PRODUCT DEFERASIROX AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY 4-(3,5-BIS(2-HYDROXYPHENYL)-(1,2,4) TRIAZOL-L-YL) BENZOIC ACID, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6179 DATED 24 OCTOBER 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 30 AUGUST 2021.
1427415 11C0042 France ⤷  Subscribe PRODUCT NAME: APIXABAN, EVENTUELLEMENT SOUS LA FORME D'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/691/001 20110520
1427415 SPC/GB11/042 United Kingdom ⤷  Subscribe PRODUCT NAME: APIXABAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/11/691/001 20110520; UK EU/1/11/691/002 20110520; UK EU/1/11/691/003 20110520; UK EU/1/11/691/004 20110520; UK EU/1/11/691/005 20110520
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.